Multidrug resistance in lymphoma: Is it time for clinical trails?

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 643-644

  Rund, Deborah ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DEXVERAPAMIL; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; RITUXIMAB; TAMOXIFEN; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

ANEMIA; B CELL LYMPHOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GENE EXPRESSION PROFILING; HUMAN; LEUKOPENIA; LIPID RAFT; MANTLE CELL LYMPHOMA; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; NOTE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CYCLOPHOSPHAMIDE; DIBENZOCYCLOHEPTENES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, NON-HODGKIN; P-GLYCOPROTEIN; PREDNISOLONE; QUINOLINES; TREATMENT OUTCOME; VINCRISTINE;

EID: 34247272508     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701286496     Document Type: Note

References (17)

1. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002) Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer, 2, pp. 48-58.
2. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. and Gottesman, M. M. (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, pp. 219-234.
3. Wilson, W. H. (2006) Drug resistance in diffuse large B-cell lymphoma. Semin Hematol, 43, pp. 230-239.
4. Niehans, G. A., Jaszcz, W., Brunetto, V., Perri, R. T., Gajl-Peczalska, K., Wick, M. R., Tsuruo, T. and Bloomfield, C. D. (1992) Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res, 52, pp. 3768-3775.
5. Bates, S. E., Wilson, W. H., Fojo, A. T., Alvarez, M., Zhan, Z. and Regis, J. (1996) Clinical reversal of multidrug resistance. Stem Cells, 14, pp. 56-63.
6. Webb, M., Brun, M., McNiven, M., Couteur, D Le and Craft, P. (1998) MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol, 102, pp. 710-717.
7. Thieblemont, C., Nasser, V., Felman, P., Leroy, K., Gazzo, S., Callet-Bauchu, E., Loriod, B., Granjeaud, S., Gaulard, P., Haioun, C., Traverse-Glehen, A., Baseggio, L., Bertucci, F., Birnbaum, D., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Salles, G., Coiffier, B., Berger, F. and Houlgatte, R. (2004) Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood, 103, pp. 2727-2737.
8. Tulpule, A. (2005) Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol, 17, pp. 466-468.
9. Morschhauser, F., Zinzani, P. L., Burgess, M., Sloots, L., Bouafia, F. and Dumontet, C. (2007) A phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma, 48, pp. 708-715.
10. Rubin, E. H., de Alwis, D. P., Pouliquen, I., Green, L., Marder, P. and Lin, Y. (2002) A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res, 8, pp. 3710-3717.
11. Finnegan, M. C., Royds, J., Goepel, J. R., Lorigan, P., Hancock, B. W. and Goyns, M. H. (1995) MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. Leuk Lymphoma, 18, pp. 297-302.
12. Ezzat, A. A., Ibrahim, E. M., Stuart, R. K., Ajarim, D., Bazarbashi, S. and El-Foudeh, M. O. (2000) Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: An interim analysis of a randomized phase III trial. Med Oncol, 17, pp. 39-46.
13. Wilson, W. H., Bates, S. E., Fojo, A. and Chabner, B. A. (1995) Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol, 121, pp. R25-R29.
14. Coiffier, B. (2006) Monoclonal antibody as therapy for malignant lymphomas. C R Biol, 329, pp. 241-254.
15. Ghetie, M. A., Marches, R., Kufert, S. and Vitetta, E. S. (2004) An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood, 104, pp. 178-183.
16. Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M. and Johns, S. J. (2003) Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics, 13, pp. 481-494.
17. Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V. and Gottesman, M. M. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, pp. 525-528.